BIOGEN INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
BIOGEN INC. (BIIB) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $30.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-06.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-02-06
- BIOGEN INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-12-31 was $18.60M.
- BIOGEN INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-09-30 was $4.60M.
- BIOGEN INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-06-30 was $7.30M.
- BIOGEN INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-03-31 was $5.40M.
- BIOGEN INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $30.70M, a 81.66% increase from fiscal 2024.
- BIOGEN INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $16.90M, a 88.42% decline from fiscal 2023.
- BIOGEN INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $146.00M, a 34.81% increase from fiscal 2022.
- BIOGEN INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $108.30M, a 498.34% increase from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $30.70M 10-K · filed 2026-02-06 | |||
| 2024-12-31 | $16.90M 10-K · filed 2026-02-06 | |||
| 2023-12-31 | $146.00M 10-K · filed 2026-02-06 | |||
| 2022-12-31 | $108.30M 10-K · filed 2025-02-12 | |||
| 2021-12-31 | $18.10M 10-K · filed 2024-02-14 | |||
| 2020-12-31 | $59.00M 10-K · filed 2023-02-15 | |||
| 2019-12-31 | $18.60M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-03 | $23.20M derived: sum of 2 quarters · filed 2021-02-03 | $30.50M derived: sum of 3 quarters · filed 2021-02-03 | $35.90M 10-K · filed 2021-02-03 |
| 2019-09-30 | $4.60M 10-Q · filed 2019-10-22 | $11.90M derived: sum of 2 quarters · filed 2019-10-22 | $17.30M 10-Q · filed 2019-10-22 | |
| 2019-06-30 | $7.30M 10-Q · filed 2019-07-24 | $12.70M 10-Q · filed 2019-07-24 | ||
| 2019-03-31 | $5.40M 10-Q · filed 2019-04-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |